Market revenue in 2023 | USD 354.6 million |
Market revenue in 2030 | USD 579.9 million |
Growth rate | 7.3% (CAGR from 2023 to 2030) |
Largest segment | Toxicology testing |
Fastest growing segment | Bioanalysis and DMPK studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Toxicology testing was the largest segment with a revenue share of 26.14% in 2023. Horizon Databook has segmented the Germany preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The country is one of the major locations for preclinical and clinical trials along with the UK in Europe. Advancements in technology and quality clinical resources are some of the primary factors expected to propel this market over the forecast period. In addition, government initiative for clinical research activities has accelerated the growth of preclinical CRO market.
Furthermore, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2021, the German pharmaceutical industry invested USD 9.26 billion (EUR 8.54 billion) in R&D. In addition, as per the German Trade and Investment (GTAI), the pharmaceutical sector had the highest research intensity among all industries at 14.4% of revenues reinvested in R&D in 2020.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account